Dedicated to the Scientific Pursuit of Better Health

JULY 2005 Vol. 19, Number 6 $29.95/Year U.S. ($39.95/Year International)

Table of Contents Carnosine and N-Acetylcarnosine Eye Drops

Carnosine and N-Acetylcarnosine Eye Drops
New Hope for Cataracts . . . . . 1
Carnosine-containing eye drops have demon-
New Hope for Cataracts
strated efficacy in treating a variety of ophthalmic by Ward Dean, MD
conditions, including corneal diseases, cataracts,

glaucoma and increased intraocular pressure.
Immune-Enhancing Palladium Compound
Poly-MVA®: Support for
Mutagenic Concerns . . . . . . . . 1
Developed after more than 40 years of
research, Poly-MVA is a useful and safe cellu-
lar nutrient that may assist in boosting
immune response and healing damaged cells.
President’s Desk . . . . . . . . . . . . 3
Dr. Mitch Fleisher joins VRP; plus product,
freedom updates.
Welcome Dr. Mitchell Fleisher to
the VRP Team . . . . . . . . . . . . . . 4
Dr. Dean welcomes Mitchell Fleisher, M.D.,
D.Ht. to VRP’s growing team of medical, sci-
entific and nutritional experts.
Customers’ Corner . . . . . . . . . . 8
• Fibrosis
• Differences Between Supplements
• Hemochromatosis
• Inflammatory Bowel Disease & BPH
• Psoriatic Arthritis
• Which is Best: BioDIM or I3C?
• DMSA and Ulcerative Colitis
• CarnoSee™ Works!
Inositol Hexaphosphate (IP6)
Fiber-Derived Support for
Mutagenic, Cardiovascular
and Immune Concerns . . . . . 10
IP6 has been shown to provide support for a
number of conditions, including various forms
of cancer, as well as kidney stones, platelet
aggregation, heart attacks and HIV.
C
ataracts are the leading cause of
blindness, accounting for about 42
percent of all cases of blindness
worldwide (affecting about 17 million
people). Twenty-eight thousand new cases
are reported every day. About 20 percent
of all people over 60 have at least the
beginning of a cataract in one or both eyes,
and that figure rises to 80 percent for peo-
ple over 75.
The most common type of cataract—a
nuclear cataract—is characterized by a
cloudy haze inside the lens (Fig. 1). This
haze is the physical manifestation of a ran-
dom clumping together of the once beauti-
Fig. 1. Nuclear cataract clouds lens.
fully ordered arrangement of lens proteins
called crystallins. As the cataract develops
forming a sharp, clear image of what we
in size and density, it reduces the amount
of light that passes through the lens and are seeing, many of the rays are spread out
scatters the light that does get through. across the retina, forming a fuzzy image.
Thus, instead of all the light rays being
Continued on page 2
focused precisely to a point on the retina,
Immune-Enhancing Palladium Compound
Poly-MVA®: Support for
Mutagenic Concerns
by Albert Sanchez, Ed.S., Ph.D.
vitamins, minerals and amino acids. This

Liver Disease in Dogs and Cats . . . 13
A regimen of the right nutrition and supple-
mentation can help pets become healthier
while addressing their liver disease.
Vinpocetine: Cognitive Enhancer’s
Role Expands to Incontinence and
Epilepsy . . . . . . . . . . . . . . . . . 14
Studies show vinpocetine may support cogni-
tive health, alleviate some symptoms of uri-
nary incontinence, and may well alleviate
some effects occurring in epilepsy.
Featured Products . . . . . . . . . 15
DHEA Under Fire: Act Now to
Protect Your Health Freedom. . . 16
The government is again waging war on a
supplement that has shown itself to be safe
and effective in a number of studies.
E
lectricity is usually associated with
plugging a cord into an outlet.
However, our body’s cells also oper-
ate through an electrochemical process.
Research indicates that a compound
known as Poly-MVA® can influence this
electrochemical process occurring in the
body, consequently “electrocuting” cancer
cells while leaving healthy cells vibrant
and alive. And while I use the term electro-
cuting to describe this process, it is less
destructive to the human body than con-
ventional ways of destroying cancer cells.
In fact, it’s highly beneficial.1
Poly-MVA contains a patented type of
palladium lipoic complex composed of the
mineral palladium bonded with the antiox-
idant lipoic acid. Poly-MVA also contains
unique compound promotes energy pro-
duction at the cellular level in both healthy
individuals and those with cancer. Cancer
cells operate in anaerobic conditions
(without oxygen) and Poly-MVA appears
to target and kill these anaerobic cells in
part through its ability to change cells’
electrochemical circuitry.1 In addition,
rather than simply destroying free radicals,
Poly-MVA converts them into energy,
indicating its potential uses may expand
beyond that of an anti-mutagenic agent.
In this article, I will discuss how a sci-
entist created Poly-MVA. I will also dis-
cuss some of Poly-MVA’s ingredients, its
mechanism of action and how it may sup-
Continued on page 6
Carnosine Eye Drops
Continued from front page
Colors may be dulled or distorted, and
there may be an annoying halo of light
around bright objects, causing a glare
effect.
Causes of Cataracts
Causes of cataracts include cumula-
tive ultraviolet radiation damage from sun
exposure, heredity, poor nutrition, smok-
ing, high blood pressure, kidney disease,
diabetes, and the long-term use of corti-
costeroids (the last two are major risk fac-
tors for cataracts). Oxidative free radicals
produced by the above-listed causes are
thought to damage vital biomolecules,
including lipids and proteins, resulting in
the clumping together of these proteins.
The antidote to free radicals, of course, is
antioxidants, such as glutathione, lipoic
acid, and vitamins C and E. Consequently,
many scientists believe that abundant con-
sumption of antioxidants may delay the
onset of cataracts.
Nutrients for Vision
Good nutrition is a key element of
effective prevention for most age-related
diseases, and cataracts are no exception. A
number of nutrients can benefit our eyes,
and may help prevent diseases such as
cataracts, glaucoma, and macular degen-
Volume 19 • Number 6 JULY 2005
Vitamin Research News
Dedicated to the Scientific Pursuit of Better Health
Publisher
Robert Watson
Medical Editor
Ward Dean, MD
Editor
David Stipech
Contributors
Randy Aronson, VMD
Albert Sanchez, Ed.S., Ph.D.
Kimberly Pryor
How to reach us: Call 1-800-877-2447; e-mail to:
mail@vrp.com; visit our website at www.vrp.com; or write to:
VRP, 4610 Arrowhead Drive, Carson City, NV 89706.
The information in this newsletter is not intended to pro-
vide personal medical advice, which should be obtained
from a medical professional, and has not been approved by
the U.S. FDA.
© 2005 by Vitamin Research Products,
Inc. (VRP) The use of information found
in Vitamin Research News for commer-
cial purposes is prohibited without writ-
ten permission from VRP. Subscriptions
are available for $29.95 per year (inter-
national $39.95).
2 JULY 2005
eration. These nutrients include the tripep-
tide glutathione (the most abundant and
important antioxidant in the human body,
critical for protecting the lens from free
radical damage); vitamins A and C; vita-
min E and some of the B vitamins; various
bioflavonoids (especially quercetin and
hesperidin) and carotenoids (especially
lutein and zeaxanthin); the amino acids
taurine, N-acetyl cysteine (a precursor of
glutathione), and acetyl L-carnitine; the
hormone melatonin; the alkaloid vinpoce-
tine; the herbs bilberry, ginkgo, and gar-
lic; the minerals zinc and selenium; and,
last but certainly not least, the saturated
fatty acid, lipoic acid (“the antioxidant’s
antioxidant”), which plays a central role
in maintaining the body’s antioxidant net-
work.1
Carnosine for Vision
Carnosine—a dipeptide consisting of
two amino acids (alanine and histidine)
connected to each other by a chemical
bond called the peptide bond — is one of
the most exciting anti-aging nutrients that
has recently become widely available.2
Based on research performed mainly by
Russian scientists, it is believed that
carnosine is effective both in preventing
and treating cataracts.3-6
The ability of carnosine to prevent
and treat cataracts is believed to be due to
its antioxidant properties and its ability to
inhibit a chemical process called glyca-
tion. Glycation leads to deleterious sub-
stances called AGEs (advanced glycation
end products). AGEs are chemical com-
plexes that result from common but unde-
sirable reactions between blood sugars,
such as glucose, and proteins in many
parts of our bodies, including the lenses of
our eyes. The sugar-protein complexes
become chemically cross-linked and
degrade cellular functions. The aptly
named AGEs are thought to be an impor-
tant factor in the aging process.
Carnosine-containing eye drops have
demonstrated efficacy in treating a variety
of ophthalmic conditions, including
corneal diseases, cataracts, glaucoma
and increased intraocular pressure. In
1997, clinical trials with carnosine-con-
taining eye drops were conducted on 109
ophthalmic patients. The results con-
firmed accelerated healing of corneal
erosions, trophic keratitis, post-herpetic
epitheliopathy, primary and secondary
corneal dystrophy, and bullous keratopa-
thy.7 Most striking, however, was the
ability of carnosine to eliminate existing
cataracts.8
Since 1979
Carnosine eye drops have been
shown to delay vision senescence in
humans, being effective in 100 percent of
cases of primary senile cataract and 80
percent of cases of mature senile
cataract. Scientists concluded that
“carnosine seems to delay the impair-
ment of eyesight with aging, effectively
preventing and treating senile cataract
and other age-related diseases.”9 Carno-
sine actually restores the proteins in the
lens by removing cross-linked carbonyl
groups, and is thought to function as a
“molecular water pump,” thereby also
helping to lower intraocular pressure.10 In
earlier experiments it was demonstrated
that applying carnosine to the conjunctiva
(the membrane covering the eye) caused
a decrease in normal intraocular pressure
and reduced prostaglandin-induced ocu-
lar hypertension (related to glaucoma) in
rabbits.11
Some scientists believe that carnosine
is ineffective if it is metabolized (broken
down) by the enzyme carnosinase.
However, studies of corneal transplants in
rabbits that were treated with one of the
metabolites of carnosine, histidine, indi-
cates that the metabolite itself may be
bioactive. Five percent histidine ointment
was applied twice daily to six transplants
for two months. All six transplants healed
and were clear. On the other hand, trans-
plants which were treated with daily
applications of one percent cortisone
became opaque and necrotic, and failed to
heal. Likewise, transplantation failed
completely in six control eyes.12 This indi-
cates that histidine may be an active por-
tion—if not the active factor—of the
carnosine molecule.
Cataract-Dissolving Analog:
N-Acetylcarnosine (NAC)
N-acetylcarnosine (NAC), like its
parent compound, carnosine, occurs natu-
rally throughout the human body. Both
compounds are found primarily in the
heart and skeletal muscles (the word
carnosine is derived from the Latin word
for flesh) and in the brain. Carnosine was
discovered in 1900 in Russia, and it is in
Russia that most of the recent research on
the N-acetylcarnosine derivative has been
carried out.13-15 Research with N-acetyl-
carnosine, as with carnosine, demon-
strates that it is effective not only in pre-
venting cataracts but also in treating them.
NAC has been shown to improve vision
by partially reversing the development of
the cataract, thus increasing the transmis-
sivity of the lens to light.
1-800-877-2447 • www.vrp.com
 The structural difference between
NAC and carnosine is that one hydrogen
atom in carnosine replaces an acetyl
group (CH3CO-), and this substitution
occurs at a nitrogen atom. An important
chemical difference between carnosine
and N-acetylcarnosine is that carnosine is
relatively insoluble in lipids (fats and
fatty compounds), whereas N-acetyl-
carnosine is relatively soluble in lipids
(as well as in water).
This means that N-acetylcarnosine
may pass through the lipid membranes
of the corneal and lens cells more easily
than carnosine, and may thereby gain
access more readily to the cells’ interior,
which is primarily aqueous. There, the
N-acetylcarnosine is gradually broken
down to carnosine (and, perhaps, to his-
tidine), which then exerts its beneficial
effects.
N-Acetylcarnosine Also
Reduces Cataracts
In one study, Russian scientists con-
ducted two randomized, double-blind,
placebo-controlled trials of six months’
and 24 months’ duration, with eye drops
consisting of a one percent aqueous solu-
tion of NAC administered as two drops
twice daily.16 They treated a total of 49
elderly patients (average age 65) with
cataracts ranging in severity from mini-
mal to advanced (but not to the point of
requiring surgery); the total number of
eyes affected was 76. Using a variety of
sophisticated optical techniques, they
monitored the condition of the cataracts,
visual acuity, and glare sensitivity.
The eyes treated with NAC were
substantially improved in six months:
the measured transmissivity of the lens-
es increased in 42 percent of the eyes, by
12 to 50 percent; in 90 percent of the
eyes, visual acuity improved by seven to
100 percent; and in 89 percent of the
eyes, glare sensitivity improved by 27 to
100 percent. These improvements were
sustained for the duration of the 24-
month trial. In no eyes was any worsen-
ing of the condition seen. By contrast,
the condition of the untreated eyes in the
control group worsened. Visual acuity
dropped in 89 percent of the controls by
17 to 80 percent after 24 months.
Another interesting study by the
same team evaluated patients between
the ages of 48 and 60, who had various
degrees of eyesight impairment, but who
did not have the symptoms of cataract.
After a course of treatment ranging from
two to six months, the conclusion was
1-800-877-2447 • email: mail@vrp.com
that the eye drops alleviated eye-tired-
ness and continued to improve eyesight
(i.e. there was more clear vision). The
subjects reported that the treatment
“brightened” and “relaxed” their eyes.
This is an important indicator that the
eye drops have a value both for preven-
tive purposes, as well as medical appli-
cations.
Conclusion
Carnosine and N-acetylcarnosine
eye drops appear to be a safe, effective
means to prevent cataracts, and to possi-
bly even treat cataracts that are forming.
Although cataract surgery is safe and
highly effective, the use of topical
carnosine or NAC eye drops may give
many people another option.
References
1. Block, W. N-Acetylcarnosine may help with cataracts. NAC
eye drops show benefits in both preventing and treating this
age-related condition. LE Magazine, Aug. 2003.
2. Bourassa, D., and Dean, W. M.D. Carnosine: A Remarkable
Multipurpose Anti-Aging Nutrient. Vitamin Research News,
Vol. 14., Num. 11, Nov. 2000.
3. Babizhayev MA, Deyev A. Free radical oxidation of lipid
and thiol groups in genesis of cataract. Biophysics (biofizika),
1986, 31, 119-125, Pergamon Journals Ltd.
4. Babizhayev MA, Deyev Al, Linberg LF. Lipid peroxidation
as a possible cause of cataract. Mech. Ageing Dev. 1988, 44,
69-89.
5. Babizhayev MA, Antioxidant activity of L-carnosine, a nat-
ural histidine-containing di-peptide in crystalline lens.
Biochem. Biophys. Acta., 1989a, 1004, 363-371.
6. Babizhayev MA, Deyev A. Lens opacity induced by lipid
peroxidation products as a model of cataract associated with
retinal disease. Biochim. Biophys. Acta., 1989b, 1004, 124-133.
7. Maichuk, IUF, Formaziuk, VE, Sergienko, VI. Development
of carnosine eyedrops and assessing their efficacy in corneal
diseases. Vestn Oftalmol, 1997, 113(6): 27-31.
8. Yuneva, M.O., Bulygina, E.R., Gallant, S.C., et al. Effect of
carnosine on age-induced changes in senescence-accelerated
mice. J Anti-Aging Medicine, 2: 1999, 337-342.
9. Wang AM, Ma C, Xie H, and Shen, F. Use of carnosine as a
natural anti-senescence drug for human beings. Biochemistry,
2000, 65(7), 869-871.
10. Baslow, MH. Function of the N-acetyl-L-histidine system
in the vertebrate eye. Evidence in support of a role as a molec-
ular water pump. J Mol Neurosci, 1998, 10(3), 193-208.
11. Ermakova, V.N., Babizhaev, M.A., Bunin, A.Ya. Effect of
L-carnosine on intraocular pressure. Byull. Eksp. Biol. Med.
1988, 105(4), 451-453.
12. Borioni, D., and Scassellati-Sforzolini, G. The action of p-
aminobenzoic acid, histidine, and cortisone on the success of
corneal transplants, Am J Ophthalmol, 1953, 36: 575-576.
13. Babizhayev MA, Yermakova VN, Sakina NL, Evstigneeva
RP, Rozhkova EA, Zheltukhina GA. N-Acetylcarnosine is a
prodrug of L-carnosine in ophthalmic application as antioxi-
dant. Clin. Chim. Acta., 1996, 254, 1-21.
14. Babizhayev MA, Yermakova VN, Deyev Al, Seguin M-C.
Imidazole-containing peptiomimetic NAC as a potent drug for
the medicinal treatment of age-related cataract in humans. J.
Anti-Aging Medicine 2000a, 2, 43-62.
15. Babizhayev MA, Yermakova VN, Semiletov yu A, Deyev
A. The natural histidine-containing di-peptide N-acetylcarno-
sine as an antioxidant for ophthalmic use. Biochemistry
(Moscow), 2000b, 65, 588-598.
16. Babizhayev MA, Deyev AI, Yermakova VN, Semiletov
YA, Davydova NG, Kurysheva NI, Zhokotskii AV, Goldman
IM. N-Acetylcarnosine, a natural histidine-containing dipep-
tide, as a potent ophthalmic drug in treatment of human
cataracts. Peptides, 2001, 22: 979-94.
Since 1979
The President’s Desk
Dr. Mitch Fleisher Joins VRP;
Plus Product, Freedom Updates
E
very month there is something excit-
ing to report in the President’s Desk
column. This month there are several
newsworthy VRP items to share with you,
plus an update on the Vitamin Wars.
First, I want to personally welcome Dr.
Mitch Fleisher to Vitamin Research
Products’ team of medical, research and
nutrition experts. Dr. Fleisher has been using
VRP’s nutritional supplements for his
patients and himself since the 1990s, when
he first became aware of Vitamin Research
Products. We welcome his clinical expertise
and his depth of VRP product knowledge.
Please see Dr. Dean’s interview with Dr.
Fleisher on page 4 of this issue of Vitamin
Research News.
Speaking of welcoming, VRP is
pleased to welcome a new product to our
line: Poly-MVA®, which research has shown
to be an effective support for those dealing
with cancer. You can read more about this
incredible nutritional product beginning on
the front page.
We also are pleased to welcome back
Inositol Hexaphosphate (IP6), which studies
have shown offers a wide range of beneficial
properties. Readers will find the article on
page 10 of interest, especially those cus-
tomers who have been asking us to offer IP6
once again. We were glad to be able to work
out supply arrangements to make it available.
News from the Vitamin Freedom Front
DHEA is now under full-scale attack,
and once again it is time to express your dis-
pleasure to your U.S. Senators and
Representatives in Washington. For more on
the threat to DHEA, please see page 16.
Also on the subject, as reported in our
May issue, the Advocate General, the senior
advisor to the European Courts of Justice
(ECJ), issued a pronouncement agreeing
with Europe’s challenge to the Food
Supplements Directive—a development seen
as positive by supplement users worldwide.
The final judgment on this issue will be
handed down July 12 by the ECJ. The judg-
ment is expected to have a significant impact
on European supplement rules—and through
international agreements and organiza-
tions—on U.S. supplement policy as well.
We will keep you posted. As always,
we’ll work together for your optimal health.
Robert Watson
President/CEO
JULY 2005 3
Welcome Dr. Mitchell Fleisher to the
Vitamin Research Products Team
by Ward Dean, M.D.
I
am pleased to have the opportunity to
welcome a great new addition to Vitamin
Research Product’s growing team of med-
ical, scientific and nutritional experts.
Given my increasing patient care work-
load, ongoing research and preparation for
upcoming clinical trials—in addition to my
role as VRP’s Medical Director—I am excit-
ed about the chance to team up with an out-
standing physician and colleague I have
known for many years—Mitchell A. Fleisher,
M.D., D.Ht.
Dr. Fleisher is a board-certified family
physician whose focus is classical homeopa-
thy, nutritional and botanical medicine,
chelation and bio-oxidative therapy with
more than 20 years experience practicing
“the gentler art and science of integrative
medicine.” Below is an interview with Dr.
Fleisher to help introduce him to our readers.
WARD DEAN, MD: Welcome, Mitch. It’s
great to have you on the VRP team.
Please tell us a little about your practice.
MITCHELL FLEISHER, MD: Thanks
for the warm welcome, Ward. I have a
homeopathic family practice. I specialize in
classical homeopathic medicine and nutri-
tion therapy, and I integrate the best of what
conventional medicine and complementary
alternative medicine have to offer.
WD: Is there anything unique about your
specific approach to treating patients?
MF: I do a very thorough evaluation as a
starting point. I spend quite a bit of time with
the patient on the initial visit—typically two-
and-a-half to three hours with a new patient
for the homeopathic and nutritional evalua-
tion. For a typical nutritional visit, the mini-
mum amount of time I spend is a half-hour. I
really give a lot of time and attention to each
patient, so that I truly understand them prior
to initiating therapy. I find that that approach
yields much better clinical results.
The main thrust is to evaluate every-
thing that is going on with the individual
patient—physically, emotionally, mentally
and spiritually. The goal is to understand the
whole person, the holistic dynamic, in order
to comprehend what kind of metabolic
imbalances we need to correct, if there are
hormonal issues, etc., what botanical and
nutritional supplements they need, and also
what kind of bioenergetic stimulation they
require. And also, I need to find out if there
4 JULY 2005
are mechanical problems, to ascertain if they
need to be referred to an acupuncturist,
osteopath, chiropractor, physical therapist,
prolotherapist, etc. I explore all the integrat-
ed therapies they may need as a whole per-
son, rather than just doing the typical, “cook-
ie-cutter” allopathic [conventional medical]
approach, i.e., “one-size-fits-all,” where as
they say, if all you have is a hammer every-
one looks like a nail. I don’t believe that
approach is effective in the long run.
Therapy must be designed to fit the unique
needs of the individual, the whole person.
WD: What ailments do you commonly
treat?
MF: I’m a doctor who deals with more than
the runny noses, colds and flus. My practice
has evolved into specializing in helping peo-
ple with really severe, chronic, degenerative
diseases and cancer. For the last two decades,
I’ve taken on the really tough cases—people
who are on lots of different conventional
medications that are making them a really
sick mess. I gradually replace the toxic drugs
with nutritional therapy and whatever else is
necessary to help stimulate their own systems
to heal themselves.
I’ve successfully treated a lot of chronic
allergies and autoimmune diseases—which
are allergies turned inside out—of all sorts,
along with all manner of chronic degenera-
tive diseases and cancer, in people of all ages,
infants, children and pregnant moms to teens
and the elderly. I’ve also done house calls and
hospice care when necessary.
WD: Explain what you mean by “aller-
gies turned inside out.”
MF: Autoimmune diseases occur when you
become allergic to yourself. Regular aller-
gies, like hay fever, sinusitis and asthma,
are your reactions to external substances;
the inflammatory mediator chemicals your
immune system generates are meant to get
rid of these foreign agents. What happens
with autoimmune diseases is that your own
body becomes a foreign agent, so it’s like
allergies turned inward—rather than exter-
nalized, they’re internalized. It represents a
deeper order of imbalance and illness.
WD: How and when did you become
acquainted with Vitamin Research Products?
MF: In the early ’90s, someone showed me
some of VRP’s products and I was interested
Since 1979
in them. Some other colleagues told me they
were having success with them. I’m constant-
ly in search of really high quality pharmaceu-
tical-grade nutrients that are hypoallergenic
and deliver precisely what they claim.
When VRP tells you there’s 150 mg of
something in a capsule, that’s exactly what’s
in it. It’s very difficult to practice as a nutri-
tional physician and prescribe things that
you’re not sure of, and have them act willy-
nilly, not as desired. Before I discovered
VRP, I had problems for years when I’d pre-
scribe something for a patient and they’d go
to the health food store to buy it without
knowing what they were really getting. They
wouldn’t get results, and we’d find out later
that the product wasn’t any good.
I much prefer—and my patients rely
upon—knowing that when I’m prescribing a
product, what’s in it is what’s supposed to be
in it. If I’m treating congestive heart failure
and I need to give a patient 450 mg of CoQ10,
I want to know that what I’m giving really has
that in it. That way, if the patient does or does-
n’t get better, I have a good idea what it is and
is not due to. I have found over time I can trust
VRP to have excellent products.
WD: What are some of the VRP products
you commonly use in your protocols?
MF: I prescribe a lot of UniZyme™, an
incredibly useful product for inflammation
of all sorts. I’ve used it in musculoskeletal
diseases, in acute trauma, in neurological
problems, in infectious inflammations.
UniZyme is extremely useful. I prescribe a
lot of R-Lipoic Acid, ‘C’ Plus, CoQ10 and
LipiControl®. That’s a really big one these
days.
WD: What kind of results are you seeing
with LipiControl®?
MF: Tremendous. We’ll likely be working
on a prospective clinical outcome study on
the nutritional treatment of hyperlipidemia
using LipiControl® and CoQ10 together.
I’ve designed a study and created patient-
and physician-assessed symptom scores and
I think we’re going to proceed with it. I’ve
seen tremendous results with LipiControl.
I follow the more sophisticated lipid
profile called the VAP cholesterol test,
which is not just a calculated value of the
portions of cholesterol particles, but a direct
measure. So when it measures HDL or
LDL, it’s actually seeing the particles them-
1-800-877-2447 • www.vrp.com
selves and is sub-fractioning it into the dif-
ferent LDL particles, as well as HDL sub-
fractions, alpha-lipoprotein, and so on. I
measure those lab results for my patients
and wean them off the Lipitor®, Pravachol®,
Crestor® or similar drugs.
One, they feel better, and two, I find
LipiControl does exactly what I want it to
do. It lowers the LDL “bad” cholesterol,
raises the HDL “good” cholesterol, controls
the alpha-lipoprotein and triglycerides, as
well as increasing vasodilation of the
peripheral tissues due to the inositol hexan-
icotinate. LipiControl does exactly what I
need it to do to correct the lipid profile of
my patients, without adverse side-effects,
and very cost-effectively.
R-Lipoic Acid I prescribe a lot because
it’s great in neuropathy, especially in dia-
betics. Also, there’s some good research
showing that it is an important, anti-aging
product for extending the lifespan. Taking
about 500 to 1,000 mg of R-Lipoic a day is
roughly equivalent to the oxidative stress
reduction on mitochondria that the
C.R.O.N. diet provides—the “calorie
restriction with optimal nutrition” diet—the
only diet that has had research showing that
it actually extends life in experimental
animals.
I also prescribe a lot of Nutri-Joint™,
which is extremely helpful for all forms of
arthritis, Carnosine—which is bar-none the
best agent to repair the ravages of dietary
excesses of sugars and refined carbohy-
drates—plus AGEBlock™ and C-Mend™,
which I think is probably one of the best
anti-mutagenesis products on the market.
I’ve found that many people with chronic
fatigue benefit greatly from the mitochondr-
ial resuscitation provided by MitoBoost I
and II™. I take several of these products
myself.
WD: So when you discovered VRP, you
began using the products for yourself as
well?
MF: Yes, I was taking other products and I
gradually switched over. My habit is to test
things on myself before I test things on my
patients, unless of course, I don’t have the
disease, so I don’t need it. I’ve been using
the VRP products for myself at least since
the mid-1990s. I feel very good about prac-
ticing what I preach and being an example
of good health to my patients.
WD: You obviously have a lot of confidence
in VRP as a physician, just as I do. From
your experience and insights, what is it
that makes VRP’s products work so well in
your protocols for the patents you treat?
MF: I find that, one, I can trust the integrity of
the products. As I mentioned, when VRP says
1-800-877-2447 • email: mail@vrp.com
there’s 150 mg of CoQ10 in it, that’s what’s in
it. I find my patients tolerate the products bet-
ter because there’s not all those problematic
adjuvants in them. If you buy CoQ10 over the
counter, you may see these big capsules or
tablets when the actual amount of CoQ10 at
150 mg is this tiny little amount. I like the fact
VRP’s supplements are hypoallergenic and
they’re in veggie caps so there’s no exposure
to potential toxins from commercially made
gelatin capsules. I’ve gained my trust in VRP
by having thousands of patients use the prod-
ucts safely and effectively over many years.
For example, I would typically give my
acute asthma patients my asthma protocol
built upon several different VRP products.
But if they go out and take just any over-the-
counter nutrients instead, I’m not sure
they’re going to get better and they often
don’t do as well as expected. But if they fol-
low my VRP protocol carefully, and I feel
certain that it’s the right regimen for them,
then I will see, time after time, good repro-
ducible results, and they gradually improve.
WD: You’ve had your practice for 20 years.
What are today’s disease trends you’re
seeing that particularly concern you?
MF: I’m seeing, in general, an increase in
chronic degenerative diseases and cancers
across the board. Rather than just having the
simple colds and flus or simple infectious
diseases, we’re witnessing a marked increase
in all manner of autoimmune disorders and
an epidemic of all sorts of cancers, and it’s
occurring in people younger and younger
and more and more severely. I’m seeing peo-
ple not just with simple allergies anymore, but
with very complicated allergies, multiple
chemical and food sensitivities.
WD: What do you attribute that to?
MF: Increasing toxicity in our environment,
which includes industrial toxins being
spewed into the environment, the poor qual-
ity of foods created by corporate agribusi-
ness, the poisoning of our air and our water,
the increasing electromagnetic stresses in
our air, etc. Everyone has a cell phone glued
to their ears—we’re going to have an
absolute plague of brain cancer in a decade
or two from now, according to the British
research literature. We’re all being exposed
to every manner of toxicity that didn’t exist
150 years ago.
In addition, we’re seeing an absolute epi-
demic of autism, which is clearly an iatrogenic
disease caused by toxicity from mercury and
aluminum in vaccines given to infants and
children and also due to industrial pollution,
particularly mercury, from coal-burning facto-
ries, as well as the superimposed, vaccine-
induced, chronic viral infections, that disrupt
normal intestinal and brain functioning.
Since 1979
WD: And what about today’s diet?
MF: Yes, right, people are living on fast foods
which are completely depleted of nutrients
and are full of fried fats, so they’re getting a
diet high in lipoxides—fatty acid oxides—
which are the most toxic, dangerous, free rad-
icals, and most commercial, non-organic
foods are virtually depleted of minerals, vita-
mins, enzymes and antioxidants. So what do
you expect to happen? What it does is if
someone has inherited a tendency towards a
disease process, it’s certainly going to come to
fruition, because we’re not respecting our
bodies, the temples of our souls, and feeding
them with healthy food rich in nutrients.
It was Hippocrates, the father of medi-
cine, who said, “May your food be your
medicine and your medicine your food.”
Nowadays, because our foods are so deplet-
ed, high quality supplementation is essen-
tial to maintain health. I rely upon VRP to
provide just that for my patients, myself
and my family.
WD: What general nutritional guidance do
you have for people today, even if they feel
healthy and are not experiencing any dis-
ease or particular ailment?
MF: It has been clearly shown that all people
can benefit from a very good quality multiple
vitamin and mineral complex. Even the
Journal of the American Medical Association
and the New England Journal of Medicine
have published articles in the last few years
stating the case, that everyone can benefit
from vitamins, because our foods are unfor-
tunately so depleted of nutritional value.
Other than taking a good multivitamin
and getting the basic essential nutrients, we
all need Omega-3 fatty acids. If you’re not
getting it from enough fatty, deep-sea fish,
you should be taking a good source of
Omega-3 fatty acids, like EthylEPA™ or
Neptune Krill Oil.
If you’re living in an inner city or an
urban area where there’s greater pollution,
you're going to need to take more of the
antioxidants, such as Vitamin C, Vitamin E,
Bioflavonoids, etc., and you may need
things like N-Acetyl Cysteine to help detox-
ify all those toxic, xenobiotic (foreign)
agents that are out there in the environment.
You have to take into account the envi-
ronment in which you’re living and the
amount of stress you’re living under.
There’s no living being in the United States
or North America today who is not exposed
to a wide array of toxins. Just eating the
typical American diet is not going to
protect you.
Taking really high quality nutrients that
are specific to your constitutional nature and
the environment in which you live is the
best health insurance policy you can buy.
JULY 2005 5

Poly-MVA®
Continued from page 1
port both individuals with mutagenic
concerns and healthy individuals.
However, first I will explain my personal
connection to the Poly-MVA story. My
wife, Julia Sanchez, died of colon cancer
in 1972 at the age of 34. At the time of her
death, I was a school principal in
Anaheim, Calif. I raised our four children
alone. I will always be inspired by her
memory. Her death, however, was not in
vain: I swore that I would never rest until
the disease that had taken her life was
vanquished. For this reason, I have
explored less invasive cancer treatment
modalities and am convinced that Poly-
MVA can play a part in cancer therapy.
Consequently, I purchased Poly-MVA for
distribution to cancer patients.
The Poly-MVA Story
Dr. Merrill Garnett, a dentist-turned
biochemist and head of the Garnett
McKeen Laboratory in Stony Brook,
New York, created palladium lipoic com-
plexes after decades of research.
Dr. Garnett’s research is based on the
theory that all normally-developed cells
contain an inward directed energy flow.
He and his son, Wade, have looked for
those pathways that alter electron flow in
the cell, from the point of view that nor-
mal cell development requires normal
energy flow.
In laboratory experiments, Dr.
Garnett found that by introducing syn-
thetic mimics of electric pathways, dys-
functional cells were destroyed selective-
ly—in other words, abnormal cells were
targeted for destruction while healthy
cells thrived. Based on this theory, Dr.
Garnett began the search to find a com-
pound that would restore healthy path-
ways for growth and normal development
within the cells—pathways missing or
deficient in dysfunctional cells.
Specifically, he searched for what’s
called a metallo-organic compound that
would act as a molecular shunt to restore
the cells’ healthy energetics.
After more than 40 years of research
and testing some 20,000 compounds, Dr.
Garnett discovered that palladium, when
combined with lipoic acid, vitamin B12 and
thiamine, created an extremely useful and
safe cellular nutrient. Subsequent toxicity
tests have shown that palladium lipoic com-
plexes are completely safe and nontoxic.2
6 JULY 2005
Mechanisms of Action
Poly-MVA is a uniquely formulated
dietary supplement containing a propri-
etary blend of palladium bonded to alpha-
lipoic acid (referred to as palladium lipoic
complexes). The supplement also con-
tains vitamins A, B1 and B12, formyl-
methionine, acetyl cysteine, plus trace
amounts of molybdenum, rhodium and
ruthenium. This formulation is designed
to provide energy for compromised body
systems by changing the electrical poten-
tial of human cells and increasing
DNA’s charge density within the cell.
Consequently, Poly-MVA may assist in
boosting immune response and healing
damaged cells.
Poly-MVA is non-toxic due to the
proprietary manufacturing process by
which palladium is sequestered within
lipoic acid. The formulation of palladium
lipoic complexes with other vitamins,
minerals and amino acids provides con-
siderable nutritional support, helping to
enable optimum functioning of essential
body systems.
The palladium lipoic complexes in
Poly-MVA work in novel ways that do
not harm the body as a whole—only the
cancer cells specifically, partially by con-
verting free radicals into a usable form of
energy. (For this reason, large amounts of
the antioxidant vitamin C shouldn’t be
given at the same time as Poly-MVA. It is
recommended that there be at least a four-
hour interval between consumption of
large quantities of antioxidants and Poly-
MVA since antioxidants scavenge and
destroy free radicals, whereas Poly-MVA
turns them into energy.)
In cancer, gene damage is caused by
adducts, chemicals that attach to the gene
and disturb its function. Palladium lipoic
complexes are essentially enzymes
known as nucleotide reductases that help
remove these carcinogenic adducts. Due
to these and other properties, the palladi-
um lipoic complexes found in Poly-MVA
increase muscle strength, raise energy
levels, protect against extracellular LDL,
chelate heavy metals, reduce need for
pain medication, improve appetite and
slow the aging process.3
Cellular metabolism is an electro-
chemical process. When the body pro-
duces energy, it is released along the elec-
tron transport chain in the form of voltage
jumps. That electrochemical energy is
captured in reactions that preserve it in
the form of adenosine triphosphate, the
energy currency of the body. Splitting
ATP into adenosine diphosphate and a
Since 1979
free phosphate molecule then fills the
body’s energy needs.
Dr. Garnett believed that electron
transfer somehow held the key to under-
standing the genetic signaling that would
transform cancer cells into healthy ones.
He sought to create a sort of “liquid tran-
sistor” consisting of a metal and an
organic compound (a metallo-organic
compound). This liquid transistor would
act as an enzyme and affect the electron
transfer to DNA. He found that a specific
combination of the metal palladium and
the organic molecule alpha-lipoic acid
rapidly and efficiently transferred elec-
tron charges to DNA. In other words,
Poly-MVA works in cancer cells by trans-
ferring excess electrons from membrane
fatty acids to DNA via the mitochondria.
Therefore, it can both quench radicals
as well as provide energy to the mito-
chondria.2,4-6
Transferring the charge in and out of
the DNA with the palladium lipoic com-
plexes changes the DNA charge as well
as the charge in all the cell membranes.
This is what is already happening in the
normal cell, in the same specific range.
Triggering this normal charge in tumors
provides therapy by way of membrane
modification.
Cell culture and animal experiments
in mice with cancerous tumors indicated
that the palladium-alpha-lipoic-acid-
thiamine compound was toxic to cancer
cells. In one experiment, mice treated
with this compound did not die from a
form of cancer that was lethal to mice not
treated with the compound. Further
analysis showed that the compound selec-
tively eliminated cancerous cells in the
animals while leaving healthy cells
alone.2
Pharmakon Laboratories also per-
formed animal studies to determine the
safety and effectiveness of palladium
lipoic complexes in the treatment of
glioblastoma, a fast-growing brain cancer.
At the beginning of the study, glioblas-
toma tumor cells were injected into mice.
When tumors had grown to 200 to 400
millimeters in volume, the mice were
divided into eight groups of ten. Four
groups were given daily intravenous doses
of either the palladium lipoic complexes or
a placebo. Four groups were tube fed pal-
ladium lipoic complexes or a placebo. The
animals administered the palladium lipoic
complexes received daily doses of 2, 1.5
or 1 milligrams per animal for four weeks.
Mice that died were dissected and tumor
volume was compared between groups.
1-800-877-2447 • www.vrp.com
 In mice that received the palladium
lipoic complexes glioblastoma tumor cell
growth was significantly reduced. All of
the intravenously treated mice showed
significant reduction in tumor size com-
pared to the placebo. Of the mice given
the palladium lipoic complexes through
tube feeding, dosages of 1 to 20 mil-
ligrams per mouse—a dose comparable
to that used in humans with cancer—sig-
nificantly shrank tumor size.7
Oncological surgeon Rudolf E. Falk
presented the first report of clinical studies
of Poly-MVA at the Adjuvant Nutrition in
Cancer Treatment Symposium in March
1994. In his work at the University of
Toronto, Dr. Falk administered Poly-MVA
intravenously to 95 patients suffering from
cancers of the breast, lung, colon, rectum,
prostate, pancreas, ovary, skin (malignant
melanoma) and brain. Ninety percent of
the subjects had failed to improve on
virtually all available conventional thera-
py. During Poly-MVA treatment, the
subjects also received moderate doses of
chemotherapy.
Only 20 to 60 percent of the patients
would be expected to survive an average
of another six months. Nine months after
being treated with the intravenous Poly-
MVA, however, 90 percent of the sub-
jects were still alive.2 Current studies on
stage IV cancers performed by certified
board oncologists reveal an improvement
of 77 percent in Poly-MVA-treated
subjects.8
The animal tube feeding experiment
mentioned above and the results achieved
by clinicians administering Poly-MVA,
indicate that oral supplementation with
Poly-MVA would be expected to achieve
the same results.
Palladium
Palladium is the binding force and
center of all the palladium lipoic complex-
es. Dr. Garnett chose palladium for specif-
ic reasons. He needed a catalyst to reestab-
lish the normal functions that had been lost
in the cancer cells. The amazing properties
of palladium, Garnett discovered, were
just right for the task. As an excellent cat-
alyst for oxygen and hydrogen, it could,
under the right circumstances, absorb
more than 900 times its volume of
hydrogen.
Dr. Garnett used the palladium to
strengthen the power of the other mole-
cules, similarly to the way iron is used to
hold the active parts of hemoglobin.2
1-800-877-2447 • email: mail@vrp.com
Lipoic Acid
Lipoic acid is one of the natural sub-
stances used to form palladium lipoic
complexes. The unusually powerful
antioxidant effect found in palladium
lipoic complexes can be partly attributed
to its lipoic acid fraction. Since this natu-
rally occurring acid is soluble in both fat
and water, palladium lipoic complexes
are able to pass across cell membranes
and work intracellularly.
When lipoic acid is connected to an
electrically charged metal substrate, and
joined with various B vitamins, the acti-
vated B12 increases the biological activ-
ity of the molecule thereby performing
that difficult journey across the blood-
brain barrier. The resulting complex, in
addition to crossing the blood brain bar-
rier, can easily and safely travel through-
out the body and into every cell. This
quality indicates that palladium lipoic
complexes may be an excellent protocol
to use in cases of brain cancer—along
with breast, prostate, colon, lung, and
stomach cancer.2
Molybdenum
Molybdenum is an essential trace
mineral crucial for the regulation of pH in
the body. Cancerous cells, depleted of
oxygen, also tend to be excessively
acidic. Anaerobic metabolism produces
acid and overly acidic cells are undergo-
ing stress.2
Rhodium and Ruthenium
Rhodium, a rare earth metal noted
for its low electrical resistance and high
corrosion resistance, is used as a catalyst
for many chemical processes. Ruthenium
is another transition metal of the platinum
group used to harden and increase
the corrosion resistance of titanium.
Ruthenium/molybdenum alloys have
been found to be superconductive.2
Other Uses for Poly-MVA
A study published in September
2004 indicates that administration of
Poly-MVA may be a potent neuroprotec-
tive agent for victims of transient
ischemic attack (TIA), cardiac arrest,
anesthetic accidents or drowning. 9
According to Frank Antonawich, one of
the researchers in this study, Poly-MVA’s
neuroprotective properties make it
extremely effective for stroke.
In addition, clinical experience indi-
cates it may support the skin health of
Since 1979
psoriasis patients.10 Clinicians have also
successfully used Poly-MVA in patients
with multiple sclerosis and lupus.2 By
enhancing the liver’s function, Poly-
MVA helps move blood out of the pelvis
via the portal vein, a process beneficial in
endometriosis.2 Poly-MVA also can be
used in pets.
Dosage
For health maintenance, take 1/4 to 1
teaspoon per day. For best absorption, it
should be taken 30 minutes prior to eat-
ing or taking other supplements.
Patients with early-stage cancer
should start with a dose of 8 teaspoons
per day, divided into 2 teaspoons four
times daily for at least two months. Then,
dosage can be reduced to 2 teaspoons
twice per day (for a total of 4 teaspoons
per day), gradually reducing further to 1
to 2 teaspoons per day.
Individuals with advanced cancer
may need the initial dose of 8 teaspoons
per day for a longer period. On average,
it takes four weeks before results are seen
and felt.
When taking Poly-MVA, a cancer
cell “die-off” can cause temporary
increases in cancer marker tests, such as
the AMAS test. Poly-MVA also may act
as a paramagnetic contrast agent, mean-
ing it may cause changes in MRI scans
that can be mistaken for cancerous
growths.
References
1. Merrill Garnett. First Pulse: A Personal Journey in
Cancer Research. 2001, 2nd edition, First Pulse Projects,
New York.
2. Milne RD, Block ML. Poly-MVA: A New Supplement in
the Fight Against Cancer. Basic Health Publications, Inc.,
New Jersey, 1-800-575-8890.
3. Sanchez A. Overcome Cancer, volume 3, series 2003.
Advanced Medicine Research Information and Education
Center, 866-426-7252.
4. Merrill Garnett. Developmental Electronic Circuits in
Cancer: Research and Treatment. Garnett McKeen Medical
Science Series, volume 1, number 2, 2002, Islip, New York.
5. Garnett McKeen. Electrogenetics: Biological Liquid
Crystal Theory. Garnett McKeen Medical Science Series,
No. 1., 2002, First Pulse Projects, New York.
6. Garnett W, Garnett M. Charge relay from molybdate
oxyradicals to palladium-lipoic complex to DNA. Paper
presented at the Conference on Oxygen Metabolites in
Nonheme Metabollichemistry, June 23, 1996, University
of Minnesota.
7. Effect of a Test Article on the Growth of A
Glioblastoma Tumor Cell Line in Nude Mice. Pharmakon
Study Number 708-GMK-001-95.
8. James W. Forsythe, MD, HMD, AMARC Inc., and
Garnett-McKeen Laboratories, Inc., Unpublished, Nine
month out-come based study with Poly-MVA, January
2004, Reno, Nevada.
9. Antonawich FJ, Fiore SM, Welicky LM. Regulation of
ischemic cell death by the lipoic acid-palladium complex,
Poly MVA, in gerbils. Exp Neurol 2004, Sep;189(1):10-5.
10. U.S. Patent 5,463,093. Palladium complexes and
methods for using same in the treatment of tumors or pso-
riasis. Filed November 26, 1993, issued October 31, 1995.
JULY 2005 7
 by Ward Dean, MD
VRP Medical Director
Fibrosis
Dear Dr. Dean,
I live in Vigo, Spain with my moth-
er. She is 56 years old (menopause
since age 36, with mild osteoporosis).
In 1998, she had surgery to remove a
retroperitoneal tumor and underwent
radiotherapy and chemotherapy.
Radiation caused an injury in her
intestine (her doctor says she has
fibrosis), so she can’t eat fiber. When
she does, the extremities of her intes-
tine “glue” and she has to go to the
hospital, where she doesn’t eat for a
day or two, until everything returns to
normal.
Her physician says surgery is the
only way to solve the problem, but it
can be a little hard to get to the spot, so
she has been avoiding it. Last year, my
mother started suffering from pain in
her knee and her fingers started to
swell.
Reading VRP’s articles, life-extension
books and Dr. Michael Colgan’s books, I
gave her: Nutri-Joint, Glucosamine,
MSM, EthylEPA™, GLA, UniZyme™,
Extend Core, Calcium/ Magnesium,
Extension Antioxidant, Extension
Phytonutrient, Resveratrol, BioDIM,
CoQ10, Lipoic Acid, Acetyl-L-Carnitine
and Primary Greens.
She stopped having pain in her
joints and the latest x-ray and MRI
shows a perfect knee (nine months
before, there was cartilage degenera-
tion). Besides that, she started sleeping
better and having more energy and she
lost 7 kg.
Nevertheless, besides Culturelle®
and L-Glutamine (and I’m not sure
these substances would help), I don’t
know what to do to cure the fibrosis in
her intestines, caused by radiation.
I know fiber is very important to
colon health and I’m worried about the
fact she can’t eat it and the fact she
gets very sick when she does.
Could you recommend something
to help her? — Ms. C.
8 JULY 2005
Dear Ms. C.,
It sounds as if you have done very
well in recommending things for your
mother’s care.
Unfortunately, she is suffering from
altered, fibrotic tissues due to the radia-
tion. Radiated tissues become cross-
linked, losing their normal flexibility and
resiliency. As you suggested, surgery may
help, if the radiated portion can be specif-
ically isolated and excised. Unfortunately,
radiated tissue doesn’t heal well, either, so
that might make the problem worse.
Potential radio-protectant substances
may help, like Resveratrol (which you are
already using) and Carnosine. Also, anti-
cross-linking substances like PABA, Oral
ChelatoRx, Benfotiamine and AGEBlock™
may help in the long run, but any improve-
ment will probably take a long time.
Ward Dean, M.D.
Differences Between Supplements
Dear Dr. Dean,
For inflammation, you’ve recom-
mended UniZyme™, Turmeric Extract
or Boswellia Serrata Extract. Should I
take them all, or just one? Can I take
them for as long as I want or just for a
certain period of time?
VRP has I3C (Indole-3-Carbinol) and
BioDIM ®. I was thinking of adding that
supplement to my current regimen of
Optimum 6, Extension Phytonutrient,
ProstaCol ® , EthylEPA™, GLA, Lipoic
Acid, CoQ10 and Carnosine to prevent
prostate cancer (it runs in my family).
I’m confused about them. What’s the
difference between them? Should I take
them both or which one would you rec-
ommend? — Mr. M.
Dear Mr. M.,
With regard to the three anti-inflam-
matory substances you mentioned, you
can take all three, as they all work by
slightly different mechanisms. However,
you may not need to.
Try one or the other, to see if it will
help. One may work better than the other,
Since 1979
depending on your particular biochemical
individuality. If one product helps a little,
but you are still having problems, you can
either bump the dose a bit, or add a second
(or third) product.
With regard to I3C or BioDIM ®, I
have no preference. Some people do bet-
ter with one product, some with the other.
As I’ve said previously, most of the
research has been done with I3C. On the
other hand, BioDIM, being the proposed
active ingredient in I3C, has some theoret-
ical advantages.
Either one should be beneficial for
you—but you may find that one works
better for you than the other due to bio-
chemical individuality.
Ward Dean, M.D.
Hemochromatosis
Dear Dr. Dean,
In past years I was on a program of
DMSA and (D) Lipoic Acid to reduce my
high levels of iron. Recently, my doctor
has switched me to IP6, HepatoGen™
and SAMe, as it appears that the other
treatment was not working. He has
also suggested that I have 250 cc of
blood drawn every couple of months. I
would appreciate your views on this
change, and/or, any suggestions that
you may have. It seems that I have
been diagnosed with a “mild” case of
hemochromatosis. — Mr. M.
Dear Mr. M.,
I think your physician is probably right
about the occasional blood draw. You may
require more blood to be removed than he
suggested. The amount should be deter-
mined by trial and error and repeated testing.
This removal of your blood will probably be
beneficial, and entails little, if any, risk.
Have you performed a Hair Analysis
(mineral) Test to determine whether there is
any need to continue/alter your oral chela-
tion program? Let me know how you do.
Ward Dean, M.D.
Continued on page 9
1-800-877-2447 • www.vrp.com
Inflammatory Bowel Disease & BPH
Dear Dr. Dean,
I enjoy your articles and com-
ments in the Vitamin Research News
very much. I am an 82-year-old, very
active male, who was diagnosed some
30-odd years ago with BPH (benign pro-
static hypertrophy—enlarged prostate).
Several months ago, I was also
diagnosed with collagenous colitis fol-
lowing a colonoscopic exam. The doctor
prescribed prednisone, but I did not like
it as it made me very “high.” When I
continued to have problems with diar-
rhea, the doctor changed my prescrip-
tion to 3 mg of Entocort®. I have been
taking three capsules per day for about
five weeks, then reduced to one capsule.
Following the prednisone experi-
ence, I started taking Imodium® as
needed, along with five capsules of
AMP Molo-Cure® in the morning and
four in the evening. I am not having
the diarrhea problem now, but in the
past six months, I have lost nearly 25
pounds. I seem not to be able to gain
weight, which is fine, as long as I don’t
continue to lose weight.
I also take VRP’s DHEA and (now
discontinued) AndroCaps. Recently I
ordered more of the DHEA, and
Culturelle® (LGG), along with
AndroAMP, which I later learned is not
to be taken if one has BPH. Why? In
January 2004, salivary tests indicated
that my testosterone was out of range
at 30L, DHEAS <2.5 Low, and morning
cortisol at 11.3 High. Is there anything
else that you can recommend? I am
about 5-foot-10 and now weigh about
158. Thank you for your help and please
continue the good work. — Mr. H.
Dear Mr. H.,
I think AndroAMP may be of benefit.
I’d disregard the relative contraindica-
tion. It is because orthodox MDs believe
testosterone contributes to prostate prob-
lems. Frankly, I believe it is the excess
estrogen that may arise due to conversion
of testosterone to estrogen. This may be
prevented by taking extra Resveratrol, as
well as helping to metabolize estrogen
with I3C (Indole-3-Carbinol) or
BioDIM®. I think boosting your testos-
terone may help to heal your colon.
I suggest adding Larch AG™, and
perhaps 30 to 100 mg of Pregnenolone
each morning to your daily regimen.
Also, try SeaCure and continue with the
Culturelle®. Hope these suggestions help.
Ward Dean, M.D.
1-800-877-2447 • email: mail@vrp.com
Psoriatic Arthritis
Dear Dr. Dean,
I just received your very in-depth
newsletter with my recent order of
Lithium Orotate. A friend of mine,
only in his 30s, is suffering from psori-
atic arthritis. His wife has done a lot of
Internet research and it seems that
there is no answer to the problem. He
has been on regular painkillers, which
are bad for his liver; and now that he is
off of them he is in agony. Can you
give me any clues as to some sort of
cure or assistance with the pain?
Thanks so much. — Mr. B.
Dear Mr. B.,
Of course, the problem is the psoria-
sis. I suggest he try Fumaric Acid, which
I’ve found to be highly effective against
most cases of psoriasis. In addition,
Acetyl L-Carnitine (1,500 to 2,000 mg
per day) and evening primrose oil (GLA)
may also help.
I’d suggest VRP’s Nutri-Joint
specifically to help restore joint carti-
lage, and anti-inflammatory substances
like UniZyme™, Turmeric Extract and
Boswellia Serrata Extract to help relieve
inflammation. Hope these suggestions
help.
Ward Dean, M.D.
Which is Best: BioDIM or I3C?
Dear Dr. Dean,
After a recent pap smear, I was
told I have mild cervical dysplasia. My
diet is 80 percent raw food; I drink
organic carrot juice twice a day and
supplement with a green food prod-
uct. I exercise regularly and am in good
health. I believe given the proper nutri-
ents, and mindset, the body will heal
itself.
I don’t know if I should take the
BioDIM® product, or the Indole-3-
Carbinol (I3C). Can you make any rec-
ommendations? Thank you. — Ms. P.
Dear Ms. P.,
Unfortunately, in this case, I’m not
sure which is best. But I am sure that you
should be on one or the other of these
substances. Most of the research has been
done with I3C. However, if you were to
Since 1979
talk with Dr. Zelig, the developer of
BioDIM, he would give a convincing
argument for DIM. Either one will most
likely be better than doing nothing.
Ward Dean, M.D.
DMSA and Ulcerative Colitis
Dear Dr. Dean,
I received my order of DMSA a few
weeks ago and was very satisfied.
Recently, I was prescribed Imuran®
(azathioprine) to stabilize my ulcera-
tive colitis. Do you know of any poten-
tial conflicts between DMSA and
Imuran®? — Mr. W.
Dear Mr. W.,
I don’t think there are any contraindi-
cations—known or imagined—between
Imuran® and DMSA.
I also suggest Culturelle®, SeaCure
and Larch AG™ for all my patients with
ulcerative colitis. I’ve also found that they
generally have low levels of Pregnenolone
and DHEA.
Ward Dean, M.D.
CarnoSee™ Works!
The following was received as an e-mail
for Dr. Bob Martin, host of Health Talk
Radio.
I listen to your show every week. I’m in
my 50s. Some weeks ago you recom-
mended CarnoSee™ to help with
intraocular pressure (IOP). It works! In
spades! IOP went from Left 18, Right
21, (after 36 months of using Xalatan®)
to 13 bilaterally in just five weeks. I
can't thank you enough. — Mr. F.
Dear Mr. F.,
Thank you for sharing your success story
using CarnoSee™. You are among untold
customers who have benefitted from
CarnoSee, which happens to be featured
on page 1 of this month’s newsletter.
Ward Dean, M.D.
For more customer questions and
answers, or to ask your own question, visit
Vitamin Research Products’ website at
www.vrp.com and go to “Dear Doctor.”
JULY 2005 9
Inositol Hexaphosphate (IP6)
Fiber-Derived Support for Mutagenic,
Cardiovascular and Immune Concerns
by Kimberly Pryor
W
e live in a delicate state of bal-
ance. Ironically, we depend on
our cells’ ability to commit sui-
cide in order for us to continue living.
This process is called apoptosis and it’s
the body’s way of weeding out once
healthy cells that have turned cancerous.
When our state of balance is disrupted,
the body loses its ability to block the
malignant transformation of normal cells
by sentencing them to die before they
become cancerous.
Once a cell has become cancerous,
it’s virtually unheard of for it to revisit its
previous state of normalcy. However, a
substance derived from dietary fiber
known as inositol hexaphosphate (IP6) or
phytic acid, forces malignant cells to
revert to a non-cancerous state, a phe-
nomenon observed in human colon can-
cer cells and other cell lines.
Scientists discovered IP6’s novel
ability to turn back the clock on cancer
cells through looking at a tumor marker
expressed on malignant and premalignant
cells. This marker, however, is absent on
normal cells. Following IP6 treatment of
cancer cells, the tumor marker was signif-
icantly suppressed, and in most IP6-treat-
ed cells the marker was completely
absent. IP6 also caused a decreased rate
of cell proliferation.1-2
It also has been suggested that IP6 can
regulate heart rate and blood pressure and
keep platelets from clumping together.3-6
Dietary IP6
IP6 occurs in fiber-rich foods—par-
ticularly cereals and wheat bran, along
with corn, soy beans, nuts (especially
peanuts), oats, seeds and rice. Scientists
have recently discovered that IP6 is a
powerful antioxidant and cancer-modu-
lating agent,7-9 but when administered in
the diet, IP6 binds with proteins, forming
insoluble complexes less readily metabo-
lized and absorbed compared to when it is
taken alone.
In fact, one group of researchers stat-
ed: “Thus, IP6, an active substance
responsible for cereal’s beneficial anti-
cancer effect, is clearly more effective
than 20 percent bran in the diet.... Intake
10 JULY 2005
of IP6 may be a more pragmatic approach
than gorging enormous quantities of fiber
for cancer prophylaxis.”10-11
Proposed Anticancer Mechanisms
IP6 exerts its effects on the body by
controlling cell division. IP6 reduces the
rate of cellular proliferation, both in vivo
and in vitro, and has exhibited an ability
to reduce DNA synthesis.12-14
Scientists have suggested that one
way IP6 may exert this cellular control is
by interfering with mineral absorption,
since iron and other minerals are impor-
tant in gene regulation.15 Studies have
shown a possible link between excess
iron and an increased risk of cancer in
animals and humans, particularly colon
cancer.16 IP6 has been shown to interfere
with iron absorption and reverse iron-
dependent augmentation of colorectal
tumor initiation. IP6 also suppresses iron-
caused oxygen generation, and almost
totally inhibits iron-caused lipid peroxi-
dation, the process where lipids turn
rancid.17-18
A concern in this regard is the possi-
bility that IP6 may deplete the body’s
mineral stores. Yet, in numerous studies,
researchers have noted no significant dif-
ferences in the level of serum or bone
minerals in rats, even after lengthy treat-
ment with IP6 and inositol.19
AbulKalam Shamsuddin, MD, PhD,
a researcher who has extensively studied
IP6 and the author of IP6: Nature’s
Revolutionary Cancer Fighter, stated that
“Certainly, its [IP6’s] hypothetical harm
connected to chelation is far less than that
of other compounds of similar usage (eg.
cancer chemotherapeutic and chemopre-
ventive agents) and are far outweighed by
the plethora of benefits.”20
The questions that arise in regard to
IP6’s ability to chelate minerals suggest
that other anticancer actions are at play.
These actions include boosting natural
defense mechanisms through the aug-
mentation of natural killer (NK) cells that
defend the body against tumor initia-
tion;21 blocking PI-3 Kinase, an enzyme
necessary for tumor promotion;22-23 alter-
ing cellular communication necessary for
Since 1979
tumor growth;24-25 and stimulating tumor
suppressor gene p53.26
New animal and cell culture experi-
ments also have indicated that IP6 works
primarily by inhibiting metastases and
blocking angiogenesis, the process of
forming new blood vessels that feed
tumors.
Angiogenesis depends on the interac-
tion between endothelial cells (cells that
line the blood vessel walls) and tumor
cells. For angiogenesis to occur, endothe-
lial cells on the blood vessel walls must
multiply or proliferate. Consequently,
Shamsuddin and colleagues investigated
IP6’s effect on both endothelial and tumor
cells.
During the in vitro experiment, IP6
inhibited the proliferation and growth of
endothelial cells. The combination of IP6
and an agent with anti-angiogenic activi-
ty was even more powerful in reducing
cell growth. IP6 also inhibited the prolif-
eration of endothelial cells derived from
human umbilical veins. In addition, IP6
significantly reduced the action of a
growth factor involved in vessel forma-
tion. In human liver cancer cells, expo-
sure to IP6 for eight and 24 hours result-
ed in a dose-dependent inhibition of
another growth factor involved in vessel
growth (vascular endothelial growth fac-
tor or VEGF).
“Thus, IP(6) has an inhibitory effect
on induced angiogenesis,” the researchers
wrote.27
In two other studies, Shamsuddin
and his fellow researchers also showed
that IP6 influences key events that stop
the spread of cancer cells.28-29
These potential mechanisms of
actions explain the outcome of a number
of studies showing IP6’s anti-mutagenic
potential in a number of different cancers.
Colon Cancer
In 1988, Shamsuddin first reported
in the journal Carcinogenesis the stun-
ning effect IP6 had on large intestinal
cancer in rats. Researchers fed 1 percent
sodium inositol hexaphosphate (Na-IP6)
to one group of animals one week prior to
inducing cancer, and to another group
1-800-877-2447 • www.vrp.com
two weeks after the last dose of a carcino-
gen was administered. Rats who took the
IP6-laced drinking water prior to carcino-
gen treatment exhibited a 35 percent
decrease in large intestinal cancer com-
pared to the control carcinogen group. The
group fed IP6 after receiving the carcino-
gen showed a similar reduction.30
Phytic acid (IP6) was also effective at
reducing the incidence of colon tumors in
conjunction with a high-risk, high-fat diet.
Colon tumor incidence in carcinogen-
treated rats plummeted from up to 70 per-
cent in the control groups to 30 percent in
the groups fed a high-risk diet (HRD) plus
phytic acid (IP6).31
IP6 may also increase its ability to
inhibit colon cancer when combined with
green tea.32
Liver Cancer
In the January-March 2005 issue of
the Asian Pacific Journal of Cancer
Prevention, researchers in Seoul, Korea
investigated the effect of IP6 and/or inosi-
tol on liver cancer in mice. The researchers
gave the animals either inositol or IP6 or a
combination of both, starting one week
prior to administration of a chemical car-
cinogen to induce liver cancer.
Supplementation with IP6, inositol or
both resulted in a significant decrease in
the size and the number of a precancerous
marker for liver cancer.33
Patients suffering from Hepatocellular
carcinoma (HCC), a common liver cancer,
usually have an extremely poor prognosis.
In the first of two experiments,
Shamsuddin and colleagues compared the
in vitro effects of IP6 on HepG2, a human
liver cancer cell line. Compared to other
cancer cell lines, HepG2 cells were
extremely sensitive to IP6, experiencing a
dose-dependent, 50 percent inhibition of
cell growth. IP6 also weakened HepG2’s
ability to form colonies.
The sequel to the experiment demon-
strated that IP6 regressed pre-existing
human liver cancer cells transplanted in
mice back to their normal, non-cancerous
state, when IP6 was injected into the
transplanted tumor cells. In addition, the
tumor weight in IP6-treated mice was 86
percent to 1180 percent less than that in
control mice.34-35
Prostate Cancer
In the last several years, a number of
in vitro and animal studies have explored
IP6’s potential role in supporting a healthy
prostate. In the September-October 2004
issue of the journal Neoplasia, University
1-800-877-2447 • email: mail@vrp.com
of Colorado researchers investigated the
growth-inhibitory effect of IP6 in andro-
gen-dependent human prostate carcinoma
cells. IP6 treatment strongly inhibited
cancer cell growth and triggered apoptosis
in the cancer cells.
According to the researchers, whose
2003 study on IP6 and androgen-inde-
pendent prostate cancer also showed sim-
ilar results, this latest study using andro-
gen-dependent prostate cancer cells indi-
cates “IP6 has promise and potential to be
effective against prostate cancer.”36-37
Breast Cancer
IP6 has been shown to inhibit car-
cinogenesis in all types of mammary can-
cer cells—those that require estrogen for
growth and those whose growth is inde-
pendent of the female sex hormone. It
accomplishes this by inhibiting DNA syn-
thesis and cell growth, and inducing dif-
ferentiation of the cancer cell lines.38-40
IP6 also enhances the anti-cancer
effects of the drugs tamoxifen and adri-
amycin. In a study published in 2003,
Shamsuddin and colleagues investigated
IP6’s ability to inhibit cancer growth in
vitro in combination with adriamycin or
tamoxifen. The researchers tested the
three substances against an estrogen
dependent human breast cancer cell line,
an estrogen independent human breast
cancer cell line, and an adriamycin-resist-
ant breast cancer cell line.
After 96 hours of treatment, much
lower concentrations of IP6 were required
to inhibit the growth of adriamycin-resist-
ant breast cancer cells than to inhibit the
estrogen-dependent human breast cancer
cells. The estrogen independent human
breast cancer cells were also highly sensi-
tive to IP6.
Cancer growth was markedly sup-
pressed when IP6 was administered prior
to the addition of adriamycin. This inhibi-
tion of cancer cell growth was especially
notable in the estrogen-dependent breast
cancer cells. In all three cell lines studied,
IP6 acted synergistically with tamoxifen.
According to the researchers, “Our
data not only confirm that IP6 alone
inhibits the growth of breast cancer cells,
but it also acts synergistically with adri-
amycin or tamoxifen” and is particularly
effective against estrogen-independent
breast cancer cells and adriamycin-resist-
ant cells.41
Leukemia
In a study published in 2002,
researchers analyzed IP6’s effects on
Since 1979
human leukemia cell lines and leukemia
cells originating in bone marrow. IP6
dose-dependently triggered cancer cell
death in all of the leukemia cell lines test-
ed. IP6 exposure caused an extensive
down modulation of genes involved in
leukemia development and an upregula-
tion of genes that inhibited leukemia’s cell
cycle. IP6 treatment of fresh bone marrow
samples where the leukemia cells origi-
nated decreased proliferation of the can-
cerous cells, but had no effect on the nor-
mal bone marrow specimens.
“Taken together, our results confirm
the antiproliferative activity of IP6,”
wrote the researchers, “and suggest that it
may have a specific antitumour effect also
in chronic myeloid leukemias, via active
gene modulation.”42
Skin Cancer
When we first reported on IP6 in
2000, a study of mouse skin cancer indi-
cated that IP6 prevented skin papillomas
when given during cancer initiation. After
initiation however, IP6 exerted little
effect.43
Since then, a study published in 2003
showed that topical application of IP6 to
the skin of mice with induced skin cancer
had a dramatic effect. Topical IP6 inhibit-
ed skin tumor development significantly
in a dose-dependent manner.44
Lung Cancer and Asbestos-Induced
Fibrosis
Scientists have also received positive
results with IP6 in regards to lung cancer
and asbestos-induced fibrosis and carcino-
ma. Studies have shown that fibrosarcoma
cells in mice treated with IP6 resulted in a
significant inhibition of tumor and size as
well as improvement of survival over the
untreated controls. In addition, IP6 treat-
ment of mice with experimental lung
metastasis resulted in a significant reduc-
tion in the number of metastatic lung
colonies.45
Due to its antioxidant properties and
its ability to chelate iron, in another study
IP6 diminished the asbestos-induced
oxidative damage that results in inflam-
mation and fibrosis in the lungs of
exposed animals, from six- to 30-fold less
than in control groups.46
Rhabdomyosarcoma
IP6 has suppressed the growth of
rhabdomyosarcoma, the most common
soft tissue sarcoma in children. Cell line
growth was reduced by 50 percent in vitro
Continued on page 12
JULY 2005 11
IP6
Continued from page 11
in a dose-dependent fashion. After two
weeks, IP6-treated mice experienced 25-
fold smaller tumors and a 49-fold reduc-
tion in tumor size after five weeks.47
Kidney Stones, Platelet Aggregation,
Heart Attacks and HIV
IP6 has been shown to support a
number of other conditions. Researchers
at the Harvard Medical School and
Massachusetts General Hospital in
Boston successfully used pure Na-InsP6
to treat idiopathic hypercalciuria, which is
associated with a high incidence of kid-
ney stones.48
Other research points to IP6’s useful-
ness in preventing platelet aggregation
(sticky platelets), a prime cause of heart
attacks and strokes. In one in vitro study
by the same researchers, stickiness was
induced in human whole blood taken
from healthy volunteers. IP6 reduced clot-
ting by 50 percent, or eliminated it alto-
gether.49
IP6’s role may also extend to control-
ling the damage inflicted upon the
myocardium (heart muscle) during heart
attacks. After a heart attack, doctors reper-
fuse (fill) the heart area with oxygenated
blood. This poses its own set of risks,
because the oxygen can churn out free rad-
icals, damaging the blood vessels and
heart muscle. Researchers successfully
used IP6 to protect the heart muscle from
superoxide damage during reperfusion.50-51
As more studies unfold, additional
properties of IP6 have been revealed.
Otake and colleagues demonstrated that
IP6 inhibited the cell destruction induced
by HIV as well as the HIV specific anti-
gen expression.52
Synergistic Effect
In his book, IP6: Nature’s
Revolutionary Cancer Fighter, Shamsuddin,
calls IP6 combined with inositol, “an anti-
cancer cocktail.” IP6 combined with inosi-
tol exerts an even more powerful suppres-
sion of cell proliferation and colorectal can-
cer than with either agent alone. This potent
“cocktail” has also been used to suppress
carcinogenesis in mammary and metastatic
tumor models.53
Shamsuddin and colleagues wrote in
an IP6 review published in the November
2003 Journal of Nutrition. “The data
strongly argue for the use of IP6 plus
12 JULY 2005
inositol in our strategies for cancer pre-
vention and treatment.”
References
1. Yang GY, Shamsuddin AM. Anticancer Res1995,
15:2479-88.
2. Sakamoto K, Venkatraman G, Shamsuddin AM.
Carcinogenesis 1993, 14:1815-19.
3. Huisamen B, Lochner A. Inositolpolyphosphates and
their binding proteins—a short review. Mol Cell Biochem
1996, 157(1-2):229-32.
4. Graf E and Empson KL. Phytic acid: a natural antioxi-
dant. J Biol Chem 1987, 262:11647-50.
5. Huang C, Ma W, Hecht SS, Dong Z. Inositol hexaphos-
phate inhibits cell transformation and activator protein 1
activation by targeting phosphatidylinositol-3’ kinase.
Cancer Research 1997, 57:2873-78.
6. Vallejo M, Jackson T, Lightman S, Hanley MR.
Occurrence and extracellular actions of inositol pentakis-
and hexakisphosphate in mammalian brain. Nature (Lond.)
1987, 330:656-58.
7. Shamsuddin AM, Ullah A, Chakravathy A. Inositol and
inositol hexaphosphate suppresses cell proliferation and
tumor formation in CD-1 mice. Carcinogenesis 1989,
10(8):1461-1463.
8. Shamsuddin AM, Baten A, Lalwani ND. Effects of inos-
itol hexaphosphate on growth and differentiation in K-562
erythroleukemia cell line. Cancer Lett 1992, 64:195-202.
9. Shamsuddin AM, Yang GY. Inositol hexaphosphate
inhibits growth and induces differentiation of PC-3 human
prostate cancer cells. Carcinogenesis 1995, 16(8):1975-
1979.
10. I Vucenik I, Yang G, Shamsuddin AM. FASEB Journal
1995, 9:A728.
11. Vucenik I, Yang G, Shamsuddin AM. Comparison of
pure inositol hexaphosphate and high-bran diet in the pre-
vention of DMBA-induced rat mammary carcinogenesis.
Nutrition and Cancer 1997, 28(1):7-13.
12. Shamsuddin AM, Yang GY. Carcinogenesis 1995,
16:1975-79.
13. Shamsuddin AM, Yang GY, Vucenik I. Novel anti-can-
cer functions of IP6: growth inhibition and differentiation
of human mammary cancer cell lines in vitro. Anticancer
Res 1996, 16:3287-92.
14. Yang GY, Shamsuddin AM. Anticancer Res 1995,
15:2479-88.
15. O’Halloran TV. Science 1993, 261:715-25.
16. Weinberg ED. Association of iron with colorectal can-
cer. Biometals 1994, 7(3):211-6.
17. Porres JM, Stahl CH, Cheng WH, et al. Dietary intrin-
sic phytate protects colon from lipid peroxidation in pigs
with a moderately high dietary iron intake. Proc Soc Exp
Biol Med 1999, 221(1):80-6.
18. Graf E, Eaton JW. Suppression of colonic cancer by
dietary phytic acid. Nutr Cancer 1993, 19(1):11-9.
19. Vucenik I, Yang GY, Shamsuddin AM. Inositol hexa-
phosphate and inositol inhibit DMBA-induced rat mamma-
ry cancer. Carcinogenesis 1995, 16:1055-58.
20. Shamsuddin AM, Vucenik I, Cole KE. IP6: a novel
anti-cancer agent. Life Sci 1997, 61(4):343-54.
21. Baten A, Ullah A, Tomazic VJ, Shamsuddin AM.
Inositol-phosphate-induced enhancement of natural killer
cell activity correlates with tumor suppression.
Carcinogenesis 1989, 10:1595-98.
22. Huang C, Ma W, Hecht SS, Dong Z. Inositol hexa-
phosphate inhibits cell transformation and activator protein
1 activation by targeting phosphatidylinositol-3’ kinase.
Cancer Research 1997, 57:2873-78.
23. Dong Z. Personal communication, 1999.
24. Morrison RS, Shi E, Kan M, Yamaguchi F, McKeehan
W, Rudnicka-Nawrot M, Palczewski K.
Inositolhexakisphosphate (InsP6): an antagonist of fibrob-
last growth factor receptor binding and activity. In Vitro
Cell Dev.Biol Anim 1994, 30A(11):783-9.
25. McKeehan W. Personal communication, 1999.
26. Saied IT, Shamsuddin AM. Up-Regulation of the
Tumor Suppressor Gene p53 and WAF1 gene expression
by IP6 in HT-29 human colon carcinoma cell line.
Anticancer Res 1998, 18(3A):1479-84.
27. Vucenik I, Passaniti A, Vitolo MI, Tantivejkul K,
Eggleton P, Shamsuddin AM.Anti-angiogenic activity of
inositol hexaphosphate (IP6). Carcinogenesis 2004,
Nov;25(11):2115-23. Epub 2004 Aug 5.
28. Tantivejkul K, Vucenik I, Shamsuddin AM. Inositol
hexaphosphate (IP6) inhibits key events of cancer metasta-
sis: I. In vitro studies of adhesion, migration and invasion
of MDA-MB 231 human breast cancer cells. Anticancer
Res 2003, Sep-Oct;23(5A):3671-9.
Since 1979
29. Tantivejkul K, Vucenik I, Shamsuddin AM. Inositol
hexaphosphate (IP6) inhibits key events of cancer metasta-
sis: II. Effects on integrins and focal adhesions. Anticancer
Res 2003, Sep-Oct;23(5A):3681-9.
30. Shamsuddin AM, Elsayed AM, Ullah A. Suppression
of large intestinal cCancer in F344 rats by inositol hexa-
phosphate. Carcinogenesis 1988, 9(4):577-80.
31. Shivapurkar N, Tang ZC, Frost A, Alabaster O. A rapid
dual organ rat carcinogenesis bioassay for evaluating the
chemoprevention of breast and colon cancer. Cancer Lett
1996, 100(1-2):169-79.
32. Challa A, Rao DR, Reddy BS. Interactive suppression
of aberrant crypt foci induced by azoxymethane in rat
colon by phytic acid and green tea. Carcinogenesis 1997,
Oct;18(10):2023-6.
33. Lee HJ, Lee SA, Choi H. Dietary administration of
inositol and/or inositol-6-phosphate prevents chemically-
induced rat hepatocarcinogenesis. Asian Pac J Cancer
Prev 2005, Jan-Mar;6(1):41-7.
34. Vucenik I, Tantivejkul K, Zhang ZS, Cole KE, Saied I,
Shamsuddin AM. IP6 in treatment of liver cancer. (I). IP6
inhibits growth and reverses transformed phenotype in
HepG2 human liver cancer cell line. Anticancer Res 1998,
18(16A):4083-90.
35. Vucenik I, Zhang ZS, Shamsuddin AM. IP6 treatment
of liver cancer. (II). Intra-yumoral injection of IP6 regress-
es pre-existing human liver cancer xenotransplanted in
nude mice. Anticancer Res 1998, 18(6A):4091-96.
36. Agarwal C, Dhanalakshmi S, Singh RP, Agarwal R. Inositol
hexaphosphate inhibits growth and induces G1 arrest and apop-
totic death of androgen-dependent human prostate carcinoma
LNCaP cells. Neoplasia 2004, Sep-Oct;6(5):646-59.
37. Agarwal C, Dhanalakshmi S, Singh RP, Agarwal R.
Inositol hexaphosphate inhibits constitutive activation of
NF- kappa B in androgen-independent human prostate car-
cinoma DU145 cells. Anticancer Res 2003, Sep-
Oct;23(5A):3855-61.
38. Thompson LU, Zhang L. Phytic acid and Minerals:
Effect on early markers of tisk for mammary and colon
carcinogenesis. Carcinogenesis 1991, 12:2041-45.
39. Shamsuddin AM. IP6: Nature’s Revolutionary Cancer-
Fighter. Kensington Books. New York, NY. 1998. Page 75.
40. Shamsuddin AM, Yang GY, Vucenik I. Novel anti-can-
cer functions of IP6: Growth inhibition and differentiation
of human mammary cancer cell lines in vitro. Anticancer
Res 1996, 16:3287-92.
41. Tantivejkul K, Vucenik I, Eiseman J, Shamsuddin AM.
Inositol hexaphosphate (IP6) enhances the anti-prolifera-
tive effects of adriamycin and tamoxifen in breast cancer.
Breast Cancer Res Treat 2003, Jun;79(3):301-12.
42. Deliliers GL, Servida F, Fracchiolla NS, Ricci C, Borsotti
C, Colombo G, Soligo D. Effect of inositol hexaphosphate
(IP(6)) on human normal and leukaemic haematopoietic
cells. Br J Haematol 2002, Jun;117(3):577-87.
43. Zarkovic M, Nakatsuru Y, Ebina K, Ishikawa T,
Shamsuddin AM. Proc Sapporo Cancer Seminar: Current
Strategies of Cancer Chemoprevention,1993.
44. Gupta KP, Singh J, Bharathi R. Suppression of
DMBA-induced mouse skin tumor development by inosi-
tol hexaphosphate and its mode of action. Nutr Cancer
2003, 46(1):66-72.
45. Vucenik I, Tomazic VJ, Fabian D, Shamsuddin AM.
Antitumor activity of phytic acid in murine transplanted
and metastatic fibrosarcoma. Cancer Lett 1992, 65:9-13.
46. Shamsuddin AM. IP6: Nature’s Revolutionary Cancer-
Fighter. Kensington Books. New York, NY. 1998. Page 80.
47. Vucenik I, Kalebic T, Tantivejkul K, Shamsuddin AM.
Novel Anticancer Function of Inositol Hexaphosphate:
Inhibition of Human Rhabdomyosarcoma in Vitro and in
Vivo. Anticancer Research 1998, 18:1377-84.
48. Ohkawa T, Ebisuno S, Kitagawa M, Marimoto S,
Miyazaki Y, Yasukawa S. Rice bran treatment for patients
with hypercalciuric stones: experimental and clinical stud-
ies. J Urol 1984, 132:1140-45.
49. Shamsuddin AM. IP6: Nature’s Revolutionary Cancer-
Fighter. Kensington Books. New York, NY. 1998. Page 84.
50. Rao PS, Liu X-K, Das DK, Weinstein GS, Tyras DH.
Protection of ischemic heart from reperfusion injury by
myo-inositol hexaphosphate, a natural antioxidant. Ann
Thorac Surg 1991, 52:908-12.
51. Shamsuddin AM. IP6: Nature’s Revolutionary Cancer-
Fighter. Kensington Books. New York, NY. 1998. Page 86.
52. Otake T, Shimonaka H, Kanai M, Miyano K, Ueba N,
Kunita N, Kurimura T. Inhibitory effect of inositol hexas-
ulfate and inositol hexaphosphoric acid (phytic acid) on
the proliferation of the human immunodeficiency virus
(HIV) in vitro (Japanese). Kansenshogaku Zasshi—J Jap
Assoc Inf Dis 1989, 63:6.
53. Vucenik I, Shamsuddin AM. Cancer inhibition by inos-
itol hexaphosphate (IP6) and inositol: from laboratory to
clinic. J Nutr 2003, Nov;133(11 Suppl 1):3778S-3784S.
1-800-877-2447 • www.vrp.com
Liver Disease in Dogs and Cats
by Randy Aronson, VMD
Director of Veterinary Division
I
magine being the second largest organ
in the body and being greatly underap-
preciated. This is the plight of our
pet’s liver, which is surpassed in size only
by the organ known as the skin. If not
functioning properly the liver can call
great attention to its importance and lead
to severe illness and death.
The liver is crucial to the following
bodily functions:
• Filtering and storing blood
• Detoxification
• Excretion of toxic byproducts of
digestion
• Metabolism of food to provide
essential vitamins and nutrients
• Blood clotting or coagulation
• Proper digestion.
As it works in silence, the liver has
an amazing ability to regenerate or
replace its cellular components. I have
seen animals with severely damaged liv-
ers make a full and complete recovery,
given an accurate diagnosis and provided
with the building blocks for cellular
recovery and regeneration.
Liver problems in pets may go unde-
tected, especially if owners aren’t aware of
these signs of liver disease or dysfunction:
• Lethargy
• Reduced appetite
• Allergies
• Constipation or diarrhea
• Weight gain or abdominal disten-
tion
• Poor skin and hair coat
• Jaundice (a yellow tinge to the
mucous membranes and eyes)
• Dark urine
• Excess salivation
• Increase urination and drinking
• Vomiting.
Veterinary Evaluation
Even to the trained eye of your veteri-
narian, only 40 to 50 percent of cats and
dogs having liver problems will be appar-
ent on physical examination—showing
jaundice and having swollen livers.
If your veterinarian suspects a liver
problem, he or she will initially recommend a
blood panel and abdominal x-rays. The blood
panel can reveal any liver enzyme abnormal-
ities, altered blood protein values or possible
anemia. The x-rays may yield information
about the liver’s size, either enlarged
(hepatomegaly) or shrunken (cirrhosis).
If there are any abnormalities, a blood
test called bile acids may be incorporated
1-800-877-2447 • email: mail@vrp.com
to assess the liver’s functionality. A fol-
low-up to the x-rays can include an ultra-
sound of the liver and possibly a skinny
needle biopsy. The biopsy is a phenome-
nal tool to completely diagnose the disease
process present. This is of great impor-
tance, since the treatment and support is
directly correlated to the specific liver dys-
function. I also utilize a procedure called
laparoscopy, which uses a small, rigid,
fiber-optic tool to directly visualize the
liver and biopsy it, if necessary.
The types of liver disease that we see
in our pets may include:
• Toxic hepatopathy, which may be due
to medical therapies for example,
acetaminophen (Tylenol®) or
Phenobarbital (used for seizures)
• Infectious Hepatitis from a vari-
ety of agents: viruses, bacteria,
parasites
• Inflammation
• Cirrhosis
• Fatty liver syndrome in cats
• Granulomatous hepatitis from
fungal disease, tumors and para-
sites
• Portosystemic shunts—a genetic
defect
• Hepatic amyloidosis
• Cancer
• Steroid hepatopathy—liver dis-
ease directly attributable to using
corticosteroids.
General Guidance
While each one of these disease enti-
ties has its own treatment, suffice it to say
there are many animals that will respond
to specific therapies for the liver.
The take-home message is that, due
to the liver’s incredible ability to replace
damaged cells, a regimen of the right
nutrition and supplementation can help
our pets become healthier while address-
ing their liver disease.
The liver is under assault daily from
the toxins we are all exposed to and from
the production of free radicals in the
body.
My recommendation for optimal
liver health for our pets is, first, to feed a
super premium dog or cat food, raw diets
or home cooked foods. I add VRP’s Dog
Vites or Cat Vites and Whole Food
Concentrate daily. For specific liver sup-
port, Pet Liver Care is an incredible supple-
ment providing ingredients like Milk Thistle,
Since 1979
Dandelion Root, Alpha Lipoic Acid and
N-Acetyl Cysteine (NAC), to name a few.
I have added SAMe and RNA, along
with two Chinese herbal formulas that
you can purchase locally, Long Dan Xie
Gan Tang and Schisandra Formula to
round out my liver support therapy.
Dr. Aronson is Director of VRP’s Veterinary
Division. By blending Eastern and Western
philosophies, he has helped animals and
animal-lovers for more than 20 years in his
veterinary practice, as well as through his
radio call-in show and published columns.
To submit a pet question to Dr. Aronson or to
subscribe to VRP’s free electronic (e-mail)
pet newsletter, visit www.vrppet.com.
Customers’ Corner
Supplement Index
Product From pages 8-9 Code
Acetyl-L-Carnitine . . . . . . . . . . .4911
AGEBlock™ . . . . . . . . . . . . . . . .1985
AndroAMP . . . . . . . . . . . . . . . . .7200
Benfotiamine . . . . . . . . . . . . . . .1011
BioDIM® . . . . . . . . . . . . . . . . . . . .8081
Boswellia Serrata Extract . . . . .5041
Calcium/Magnesium . . . . . . . . .7451
CarnoSee™ . . . . . . . . . . . . . . . .9126
Carnosine . . . . . . . . . . . . . . . . . .4112
CoQ10 . . . . . . . . . . . . . . . . . . . . .6321
Culturelle® . . . . . . . . . . . . . . . . . .9182
DHEA . . . . . . . . . . . . . . . . . . . . . .6371
DMSA . . . . . . . . . . . . . . . . . . . . .8111
EthylEPA™ . . . . . . . . . . . . . . . . .3331
Extend Core . . . . . . . . . . . . . . . .3203
Extension Antioxidant . . . . . . .2186
Extension Phytonutrient . . . . . .2180
Fumaric Acid . . . . . . . . . . . . . . .6671
GLA . . . . . . . . . . . . . . . . . . . . . . .3250
Glucosamine Complex . . . . . . .3601
Hair Analysis Test . . . . . . . . . . .9808
HepatoGen™ . . . . . . . . . . . . . . .1600
I3C (Indole-3-Carbinol) . . . . . . .6041
IP6 . . . . . . . . . . . . . . . . . . . . . . . .1351
L-Glutamine . . . . . . . . . . . . . . . .4211
Larch AG™ . . . . . . . . . . . . . . . . .8101
Lipoic Acid . . . . . . . . . . . . . . . . .3451
Lithium Orotate . . . . . . . . . . . . .7241
MSM . . . . . . . . . . . . . . . . . . . . . .5383
Nutri-Joint . . . . . . . . . . . . . . . . .5241
Optimum 6 . . . . . . . . . . . . . . . . .3310
Oral ChelatoRx . . . . . . . . . . . . . .1820
PABA . . . . . . . . . . . . . . . . . . . . . .1281
Pregnenolone . . . . . . . . . . . . . . .5713
Primary Greens . . . . . . . . . . . . .5226
ProstaCol® . . . . . . . . . . . . . . . . . .1620
Resveratrol . . . . . . . . . . . . . . . . .5512
SAMe . . . . . . . . . . . . . . . . . . . . .4421
SeaCure . . . . . . . . . . . . . . . . . . .9119
Turmeric Extract . . . . . . . . . . . .5102
UniZyme™ . . . . . . . . . . . . . . . . .1630
JULY 2005 13
Vinpocetine: Cognitive Enhancer’s Role
Expands to Incontinence and Epilepsy
by Kimberly Pryor
T
he periwinkle has long been an
established part of summer gar-
dens. But research has revealed
that this flower is more than just a pretty
addition to landscaping. Studies have
indicated that vinpocetine, a natural sub-
stance derived from vincamine, an extract
of the periwinkle, may support cognitive
health, alleviate some of the symptoms of
urinary incontinence, and, when adminis-
tered intravenously in animals, alleviate
some of the negative effects that occur in
epilepsy.
Early experiments with vinpocetine
indicated it has five main mechanisms of
action. It can selectively enhance brain
circulation and the brain’s use of oxygen
without significantly altering circulation
throughout the body. Vinpocetine also
increases the brain’s tolerance toward
hypoxia (oxygen deficiency) and
ischemia (obstructed blood flow) and acts
as an anticonvulsant. In addition, it
inhibits the enzyme phosphodiesterase
(PDE)-1, which breaks down adenosine
monophosphate, an important nucleotide
that the body makes from the cellular
energy molecule known as adenosine
triphosphate (ATP). Finally, vinpocetine
stops blood cells from sticking together.
Later studies confirmed the above effects
and pinpointed other mechanism of
actions of vinpocetine (including its abil-
ity to act as a sodium channel blocker).1
Cognitive Support
Many vinpocetine studies have
focused on its potential ability to enhance
brain function. Vinpocetine increases
blood circulation and metabolism in the
brain, which may be why vinpocetine
reduced the loss of neurons due to
decreased blood flow in animal studies.2
In three studies of older adults with
memory problems associated with poor
brain circulation or dementia-related dis-
ease, vinpocetine-treated subjects experi-
enced significantly more improvement
than placebo-treated subjects on global
cognitive tests reflecting attention, con-
centration, and memory.2
In one study, the efficacy and toler-
ance of orally administered vinpocetine
was investigated in patients suffering
14 JULY 2005
from mild to moderate organic psycho-
logical syndromes, including primary
dementia. In the placebo-controlled, ran-
domized, double-blind trial, 203 patients
received daily for 16 weeks either 10 mgs
of vinpocetine three times per day, 20
mgs of vinpocetine three times per day, or
a placebo three times per day.
On both the lower and higher doses,
the patients treated with vinpocetine
experienced statistically significant
improvements in cognitive performance
compared to the placebo groups.
Vinpocetine was also superior to placebo
in improving ratings of the “severity of
illness.”
There were no clinically relevant
side-effects reported and the frequencies
of adverse events between patients treat-
ed with vinpocetine and placebo were
comparable.3
Urinary Incontinence
Although vinpocetine is best known
for the part it plays in cognitive support,
researchers also have unearthed another
potential role for this substance—urinary
incontinence. The standard drugs avail-
able for incontinence and low compliance
bladder are limited by a low clinical effi-
cacy and significant side effects.
Previous in vitro studies indicated
that the enzyme known as phosphodi-
esterase (PDE)-1 (which breaks down
adenosine monophosphate) may be
involved in the regulation of contractility
in the bladder’s layer of muscle. Due to
this connection, researchers decided to
investigate the effect of vinpocetine, a
PDE-1 inhibitor, in people who did not
respond to standard drug therapy and who
had been told that surgery is needed to
correct the problem.
The 19 subjects (10 women and nine
men, average age 56) were given 5 mg per
day of vinpocetine for two weeks, then 10
mg per day for another two weeks. In 11
subjects (57.9 percent) clinical symptoms
and/or the holding and storage of urine
were improved. In eight subjects, there
was a marked improvement after vinpoce-
tine treatment. In three of the subjects,
there was a slight improvement after treat-
ment. The other eight subjects did not
respond to vinpocetine.4
Since 1979
Although the researchers called the
initial data preliminary, they pointed out
that this study represents the first evi-
dence that a phosphodiesterase (PDE)-1
enzyme inhibitor such as vinpocetine
“may be a novel approach to the treat-
ment of lower urinary tract disorders.”
Vinpocetine appears to be more
effective in what’s known as urge incon-
tinence because it relaxes or desensitizes
the bladder, whereas other agents that
stimulate and strengthen the pelvic floor
are more effective for stress incontinence.
Urge incontinence is when an individual
experiences involuntary passage of urine
occurring soon after a strong sense of
urgency to void. Stress incontinence is
the inability to prevent escape of small
amounts of urine during laughing, cough-
ing, sneezing or lifting.5
Epilepsy
Vinpocetine also has been investigat-
ed for its potential role in epilepsy. One
group of researchers induced convulsions
in guinea pigs by using an agent called 4-
aminopyridine (4-AP). The researchers
injected the animals with vinpocetine and
then observed its effects.
Vinpocetine inhibited the undesirable
electroencephalogram (EEG) changes
induced by 4-AP. In addition, it prevented
the hearing loss that usually accompanies
4-AP administration.6
The researchers concluded, “Vinpocetine
could be a promising alternative for the
treatment of epilepsy.”
References
1. Kiss B, Karpati E. [Mechanism of action of vinpoce-
tine] [Article in Hungarian] Acta Pharm Hung 1996,
Sep;66(5):213-24.
2. McDaniel MA, Maier SF, Einstein GO. “Brain-specific”
nutrients: a memory cure? Nutrition 2003, Nov-
Dec;19(11-12):957-75.
3. Hindmarch I, Fuchs HH, Erzigkeit H. Efficacy and tol-
erance of vinpocetine in ambulant patients suffering from
mild to moderate organic psychosyndromes. Int Clin
Psychopharmacol 1991, Spring;6(1):31-43.
4. Truss MC, Stief CG, Uckert S, Becker AJ, Schultheiss
D, Machtens S, Jonas U. Initial clinical experience with the
selective phosphodiesterase-I isoenzyme inhibitor vinpoce-
tine in the treatment of urge incontinence and low compli-
ance bladder. World J Urol 2000, Dec;18(6):439-43.
5. Hampel C, Gillitzer R, Pahernik S, Melchior SW,
Thuroff JW. [Drug therapy of female urinary inconti-
nence] [Article in German] Urologe A 2005,
Mar;44(3):244-55.
6. Sitges M, Nekrassov V. Vinpocetine prevents 4-
aminopyridine-induced changes in the EEG, the auditory
brainstem responses and hearing. Clin Neurophysiol 2004,
Dec;115(12):2711-7.
1-800-877-2447 • www.vrp.com
 Featured Products
Poly-MVA® New
Poly-MVA® contains a Product!
patented type of palladium
lipoic complex, the mineral
palladium bonded with the antioxidant
lipoic acid. Palladium, when combined
with lipoic acid, vitamin B12, thiamine
and other minerals and amino acids, is an
extremely useful cellular nutrient. This
unique compound promotes cellular ener-
gy production and can pass through the
blood-brain barrier to act as an antimuta-
genic agent.* A novel antioxidant, Poly-
MVA converts free radicals into energy,
helping to alleviate DNA and RNA dam-
age.* The result of more than 40 years of
research, Poly-MVA is safe and nontoxic.
Suggested Use: For health maintenance: 1/2
to 1 teaspoon per day, 30 minutes prior to
eating or taking other supplements. For exist-
ing cellular damage: 8 teaspoons per day,
divided into 2 teaspoons four times per day for
at least two months. Then, reduce dosage to 2
teaspoons twice per day, gradually reducing to
1 to 2 teaspoons. More severe cases may need
the 8 teaspoons dose for a longer period.
• 9127 8 ounces (liquid) $215.00
• 91275 Six 8-ounce bottles $1,075.00
(Buy 5, get one free)
LipiControl®
Heart health remains a primary concern
for many people and effective, natural
products exist to promote heart health.
Designed for those who want help main-
taining healthful levels of fats and sterols
in the blood, LipiControl® is a powerful
and effective combination of herbs and
vitamins that have been shown to support
and manage healthy lipid levels, vascular
(blood vessel) function and circulation.*
LipiControl combines the non-flush form
of niacin (vitamin B3) with balanced
amounts of gamma oryzanol, beta-sitos-
terol, red yeast and gugulipid, standard-
ized to 10 percent guggulsterones. It
would be prudent for individuals who take
LipiControl to consider supplementing
with Coenzyme Q10, another supplement
well-documented for heart health, in addi-
tion to practicing good dietary choices.
Recommended Dosage: Two capsules three
times per day.
• 1960 180 capsules $49.95
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
1-800-877-2447 • email: mail@vrp.com
InoCell™ IP6
(Inositol Hexaphosphate)
IP6 is a fiber-derived nutrient
shown to reduce cell prolif-
IP6 Is
eration and stop angiogene-
Back!
sis.* IP6 is a powerful antiox-
idant, but when administered
in the diet, IP6 binds with proteins, forming
insoluble complexes less readily metabolized
and absorbed compared to when it is taken
alone. IP6’s role in prostate, colon, breast,
lung, and liver health may be enhanced
when combined with inositol.* These two
nutrients also play a part in heart health
through their ability to influence platelet
aggregation.*
Recommended Dosage: Two capsules two
times per day on an empty stomach.
• 1351 120 capsules (400 mg) $23.95
Vinpocetine
Research indicates that Vinpocetine increas-
es cerebral ATP function and enhances oxy-
gen and glucose production because of its
selective effects on improving cerebral circu-
lation.* It also aids in relaxing smooth mus-
cles (vascular wall), increasing blood flow.*
Recommended Dosage: One capsule three
times per day with meals.
• 7141 90 capsules (10 mg) $19.95
DHEA
Of all the body’s hormones, dehy-
droepiandrosterone (DHEA) is found in
the greatest amounts. Studies show that
DHEA levels drop significantly in men and
women after age 35. It is a metabolic
precursor to other hormones and is criti-
cal to the optimal function of almost
every component of the body.* DHEA is
the crucial natural counter balance to the
immune suppressive, catabolic hormone
cortisol. We recommend that DHEA be
taken once daily in the morning to mimic
the body’s normal rhythm.
Recommended dosage: 10 to 25 mg for
women, 25 to 100 mg for men.
• 6361 60 capsules (10 mg) $6.95
• 6371 60 capsules (25 mg) $7.95
• 6381 60 capsules (50 mg) $11.95
• 6391 60 capsules (100 mg) $19.95
Since 1979
CarnoSee™
(Carnosine Eye Drops)
CarnoSee™ eye drops contain 1 percent
N-acetylcarnosine, an antioxidant and
anti-glycation agent. Glycation is a
process (that increases with age) in which
sugars and proteins bind together, lead-
ing to tissue damage. CarnoSee also con-
tains the antioxidants vitamins A and E,
plus ophthalmic lubricating agents to
combat “dry eye” and other forms of eye
irritation. Each package of CarnoSee con-
tains five 2-ml resealable vials.
Recommended Dosage: One or two drops
in each eye one to four times per day or as
directed by a physician.
• 9126 5 vials (2 ml each) $32.00
Product Updates
DermAmour®
Please note that DermAmour® anti-aging skin
cream has been discontinued by the manu-
facturer. Available only while supplies last.
• 1538 4 fluid ounce cream $29.95
Coral Pure — Discontinued
Coral Pure coral calcium, product 9171,
has been discontinued by the manufac-
turer and is no longer available. A sug-
gested alternative is Coral Balance, below.
Coral Balance
Coral provides a good source of dietary
calcium. Vitamin D3 promotes calcium
absorption from the intestine. Betaine
HCL yields HCL in the stomach, which
helps solubilize the coral calcium for bet-
ter absorption.
Recommended Dosage: Two capsules twice
per day with meals.
• 9201 120 capsules $19.95
Questions? Call Us!
If you have questions about a
product, dosage or how to take it,
please call us at 1-800-877-2447.
JULY 2005 15
DHEA Under Fire: Act Now to
Protect Your Health Freedom
VRP Staff
O
nce again the government is wag-
ing war on a supplement that has
shown itself to be safe and effec-
tive in a number of studies.
On May 26, 2005, Senators John
McCain (R-Ariz.), George Allen (R-Va.)
and Chuck Grassley (R-Iowa) introduced
a new Senate bill, S. 1137. This flawed
piece of legislation will add DHEA to the
list of federally controlled anabolic
steroids, prohibiting easy, affordable
access to a hormone used safely by mil-
lions of people.
DHEA (dehydroepiandrosterone) is
secreted by the adrenal glands. Involved
in the manufacture of testosterone, estro-
gen, progesterone, and corticosterone,
DHEA declines with age.
DHEA is one of the most researched
hormones in the medical literature.
Studies have shown that it safely
improves menopausal symptoms, decreas-
es insulin resistance and abdominal fat,
stimulates the growth of human brain
cells, supports cardiac health, improves
immune function and plays a role in the
health of lupus patients. In addition,
16 JULY 2005
Printed in the U.S.A.
4610 Arrowhead Drive, Carson City, NV 89706
If we do not take action,
Senate Bill 1137 will
prohibit over-the-counter
sales of DHEA and put an
end to easy-and-affordable
access by classifying it as an
anabolic steroid.
DHEA supplementation has extended the
lifespan of animals.
Furthermore, this hormone’s safety
has been demonstrated in a number of
studies. Scientific evidence does not sup-
port claims that DHEA can cause adverse
side effects such as liver damage, stroke,
heart disease and cancer.
In addition, millions of middle-aged
and older adults have consumed DHEA
daily and have experienced none of the
negative effects the S. 1137 authors pur-
port it causes. However, for reasons that
have nothing to do with protecting the
public, DHEA has come under fire.
• w w w. v r p . c o m • 1-800-877-2447
Vitamin
Research
Products
Since 1979
If we do not take action, Senate Bill
1137 will prohibit over-the-counter sales
of DHEA. This means that those who
have relied on this supplement to enhance
their health will find they no longer have
easy and affordable access. Instead,
DHEA will become a controlled sub-
stance, and will be classified as an ana-
bolic steroid. To stop this from happen-
ing, we must voice our opposition.
Please write to your senators and
ask them to oppose S. 1137. Or, to send
an e-mail to your senators, go to
www.saveoursupplements.org. By plac-
ing your ZIP code into the designated box
in the top left corner and clicking on go,
you will send an e-mail to your senators
letting them know you oppose any legis-
lation that would make DHEA illegal.
In addition to the e-mail, sending a
fax or U.S. mail letter with a handwritten
note can ensure your message doesn’t get
lost in the shuffle.
By working together to defeat S. 1137,
we can ensure that everyone can obtain one
of nature’s most important hormonal tools
for enhancing the quality of life.
• email: mail@vrp.com
PRSRT STD
U.S. POSTAGE
PA I D
PERMIT #625
RENO, NV